Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Anti-angiogenic therapies, including vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors (TKIs), have transformed cancer management by targeting tumor vasculature and suppressing metastasis. However, these agents can induce renal toxicities such as hypertension, proteinuria, and acute kidney injury (AKI), which may affect treatment continuity and outcomes. Data from sub-Saharan Africa on these adverse effects remains scarce.
This was a retrospective cross-sectional study conducted at the Aga Khan University Hospital, Nairobi, oncology clinic. Medical records of adult patients receiving anti-angiogenic therapy between January 2020 and December 2024 were reviewed. Demographic data, comorbidities, treatment regimens, renal parameters, and renal adverse effects were analyzed. AKI was defined by KDIGO criteria, while proteinuria and hypertension were recorded from clinical and laboratory documentation.
Eighty-eight patients were included. Nine patients (10.2%) developed proteinuria: eight were on bevacizumab and one on lenvatinib. Among those on bevacizumab, one had resolution with angiotensin receptor blocker and steroids, three had therapy held, and in four, the proteinuria resolved spontaneously. Five patients (5.7%) developed AKI—three on bevacizumab and two on lenvatinib. Both patients on lenvatinib experienced nausea, vomiting, and AKI; one required renal replacement therapy. Ten patients (11.4%) developed new-onset hypertension: six on bevacizumab and four on lenvatinib. Of those on bevacizumab, four were managed with antihypertensive therapy, one had treatment held, and one had therapy interrupted. Among lenvatinib recipients, two had dose reductions and two had treatment held completely. Overall, the prevalence of new-onset AKI was 4.5%.
Renal adverse effects related to anti-angiogenic therapy were observed in approximately 10% of patients, with bevacizumab predominantly associated with proteinuria and hypertension, and lenvatinib with AKI and hypertension. Most events were manageable through dose modification or supportive therapy. These findings highlight the importance of close renal monitoring, early recognition of toxicity, and individualised management to maintain oncologic efficacy while preserving renal function. Larger multi-center studies are needed to confirm these findings in the African oncology populations.
